XBiotech
XBIT
32 hedge funds and large institutions have $12.5M invested in XBiotech in 2016 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 14 increasing their positions, 8 reducing their positions, and 9 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 8
0.11% less ownership
Funds ownership: 4.21% → 4.09% (-0.11%)
15% less capital invested
Capital invested by funds: $14.7M → $12.5M (-$2.22M)
16% less funds holding
Funds holding: 38 → 32 (-6)
67% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$296K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$269K |
| 3 |
State Street
Boston,
Massachusetts
|
+$118K |
| 4 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
+$116K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$38K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$452K |
| 2 |
NFA
Nationwide Fund Advisors
Columbus,
Ohio
|
-$296K |
| 3 |
Millennium Management
New York
|
-$171K |
| 4 |
Goldman Sachs
New York
|
-$151K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$113K |
XBIT Hedge Fund Activity: Q1 2016 in Review
32 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q1 2016, worth a combined $12.5M — down 15% from $14.7M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of XBIT and 3 opened new positions — a net loss of 6 holders — while 8 trimmed existing stakes and 14 added.
The largest buyer was BlackRock Fund Advisors, adding an estimated $296K. The largest seller was Oxford Asset Management, exiting entirely with an estimated $452K sold.
- 32 institutional investors held XBiotech (XBIT) as of Q1 2016, down from 38 in Q4 2015.
- Funds reported $12.5M of XBiotech stock for Q1 2016, down 15% quarter-over-quarter.
- 3 funds opened new XBiotech positions in Q1 2016 and 9 closed out, a net change of -6 holders.
- The largest XBiotech buyer in Q1 2016 was BlackRock Fund Advisors, an estimated $296K added.
- The largest XBiotech seller in Q1 2016 was Oxford Asset Management, an estimated $452K sold.
Based on aggregated 13F filings for Q1 2016.